{
    "nct_id": "NCT06596694",
    "official_title": "A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers",
    "inclusion_criteria": "The main inclusion criteria include but are not limited to the following:\n\n* Has one of the following cancers:\n\n  * Unresectable or metastatic colorectal cancer.\n  * Advanced and/or unresectable biliary tract cancer (BTC)\n  * Hepatocellular carcinoma (HCC) not amenable to locoregional therapy\n* Has received prior therapy for the cancer.\n* Has recovered from any side effects due to previous cancer treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "The main exclusion criteria include but are not limited to the following:\n\n* Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or has current ILD/pneumonitis, and/or suspected ILD/pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening\n* Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses\n* Has evidence of any leptomeningeal disease\n* Has clinically significant corneal disease\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease\n* Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection",
    "miscellaneous_criteria": ""
}